ArticlePloS one2011
Theiler's murine encephalomyelitis virus as a vaccine candidate for immunotherapy.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 26 citations in OpenAlex.
- TMEM119+ microglia MHC class I restricted antigen presentation impacts CD8 T cell memory, effector status, and blood-brain barrier disruption during neurotropic virus infection.Research square · 2026Article
- Virus-specific CD8 T cells rapidly populate and persist in skull bone marrow after brain infection.Research square · 2026Article
- Discrete class I molecules on brain endothelium differentially regulate neuropathology in experimental cerebral malaria.Brain : a journal of neurology · 2024Article
- C-type lectin receptor DCIR contributes to hippocampal injury in acute neurotropic virus infection.Scientific reports · 2021Article
- Transcriptome analysis following neurotropic virus infection reveals faulty innate immunity and delayed antigen presentation in mice susceptible to virus-induced demyelination.Brain pathology (Zurich, Switzerland) · 2021Article
- TCF-1 controls TNature immunology · 2021Article
- CARD9 Deficiency Increases Hippocampal Injury Following Acute Neurotropic Picornavirus Infection but Does Not Affect Pathogen Elimination.International journal of molecular sciences · 2021Article
- Microglia and Perivascular Macrophages Act as Antigen Presenting Cells to Promote CD8 T Cell Infiltration of the Brain.Frontiers in immunology · 2021Article
- Brain cancer induces systemic immunosuppression through release of non-steroid soluble mediators.Brain : a journal of neurology · 2020Article
- Developing Picornaviruses for Cancer Therapy.Cancers · 2019Review
- Non-equivalent antigen presenting capabilities of dendritic cells and macrophages in generating brain-infiltrating CD8Nature communications · 2018Article
- Brain atrophy in picornavirus-infected FVB mice is dependent on the H-2DFASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2017Article
- Superior isolation of antigen-specific brain infiltrating T cells using manual homogenization technique.Journal of immunological methods · 2016Article
- Modulatory effects of perforin gene dosage on pathogen-associated blood-brain barrier (BBB) disruption.Journal of neuroinflammation · 2016Article
- Enhancing the Tumor Selectivity of a Picornavirus Virotherapy Promotes Tumor Regression and the Accumulation of Infiltrating CD8+ T Cells.Molecular cancer therapeutics · 2016Article
- The Effect of Vector Silencing during Picornavirus Vaccination against Experimental Melanoma and Glioma.PloS one · 2016Article
- Article
- A CD8 T-cell epitope variant enhances immune targeting to a recombinant picornavirus vaccine antigen.Viral immunology · 2014Article
- Picornavirus infection leading to immunosuppression.Future virology · 2014Article
- An elite controller of picornavirus infection targets an epitope that is resistant to immune escape.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
The induction of sterilizing T-cell responses to tumors is a major goal in the development of T-cell vaccines for treating cancer. Although specific components of anti-viral CD8+ immunity are well characterized, we still lack the ability to mimic viral CD8+ T-cell responses in therapeutic settings for treating cancers. Infection with the picornavirus Theiler's murine encephalomyelitis virus (TMEV) induces a strong sterilizing CD8+ T-cell response. In the absence of sterilizing immunity, the virus causes a persistent infection. We capitalized on the ability of TMEV to induce strong cellular immunity even under conditions of immune deficiency by modifying the virus to evaluate its potential as a T-cell vaccine. The introduction of defined CD8+ T-cell epitopes into the leader sequence of the TMEV genome generates an attenuated vaccine strain that can efficiently drive CD8+ T-cell responses to the targeted antigen. This virus activates T-cells in a manner that is capable of inducing targeted tissue damage and glucose dysregulation in an adoptive T-cell transfer model of diabetes mellitus. As a therapeutic vaccine for the treatment of established melanoma, epitope-modified TMEV can induce strong cytotoxic T-cell responses and promote infiltration of the T-cells into established tumors, ultimately leading to a delay in tumor growth and improved survival of vaccinated animals. We propose that epitope-modified TMEV is an excellent candidate for further development as a human T-cell vaccine for use in immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.